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Abstract. In southeast Asia, the widespread high prevalence of counterfeits tablets of the vital antimalarial artesu-
nate is of great public health concern. To assess the seriousness of this problem, we quantified the amount of active
ingredient present in artesunate tablets by liquid chromatography coupled to mass spectrometry. This method, in
conjunction with analysis of the packaging, classified tablets as genuine, substandard, or fake and validated results of the
colorimetric Fast Red TR test. Eight (35%) of 23 fake artesunate samples contained the wrong active ingredients, which
were identified as different erythromycins and paracetamol. Raman spectroscopy identified calcium carbonate as an
excipient in 9 (39%) of 23 fake samples. Multivariate unsupervised pattern recognition results indicated two major
clusters of artesunate counterfeits, those with counterfeit foil stickers and containing calcium carbonate, erythromycin,
and paracetamol, and those with counterfeit holograms and containing starch but without evidence of erythromycin or
paracetamol.
INTRODUCTION
Counterfeit drugs, as defined by the World Health Orga-
nization (WHO), are those that are “deliberately and fraudu-
lently mislabeled with respect to identity and/or source . . .
with fake packaging, with the wrong ingredients, without ac-
tive ingredients, or with insufficient active ingredient.”1 Pub-
lic health is at increasing risk because of an apparent growing
global epidemic of the manufacture and trade of counterfeit
pharmaceuticals. For example, in Haiti, India, Nigeria, and
Bangladesh some 500 children died of acute renal failure after
ingesting counterfeit paracetamol (acetaminophen) and
cough syrup made using diethylene glycol, a renal toxin.2,3
Although there are few accurate estimates of the scale of the
problem, only a few counterfeit drug incidents are reported to
the appropriate enforcement agencies; thus, numbers of those
affected by counterfeit drugs are likely to be grossly under-
estimated.4,5
Since the late 1990s, counterfeit drugs manufactured to
mimic antimalarial medicines have been detected in increas-
ing numbers.6–8 Each year, 300–500 million people in Asia
and Africa contract Plasmodium falciparum malaria and ap-
proximately 1.5 million die.9 The control of malaria, which is
dependent on effective antimalarial drugs and bed nets, has
been severely hampered by a widespread increase in the
prevalence of drug-resistant malaria parasites.10 Artesunate,
an artemisinin derivative, is widely and increasingly used in
the treatment of P. falciparum malaria in many southeast
Asian and African countries and is vital for the therapy of
drug-resistant malaria.11 In Asia, artesunate has become the
target of an extremely sophisticated and prolific counterfeit
drug trade that includes the counterfeiting of both the arte-
sunate tablets and packaging, which look extremely similar to
the authentic product.12–15 In response to this public health
problem, Green and others developed a colorimetric Fast
Red TR dye test16 that rapidly and inexpensively screens for
the presence of artemisinin-derived compounds such as arte-
mether, artesunate, and dihydroartemisinin in tablets. There
are at least 10 different manufacturers of artesunate tablets in
Asia. The tablets produced by them have a stated artesunate
content of 50 mg. Surveys conducted in 1999–2000 and 2001–
2002 in Cambodia, Lao People’s Democratic Republic
(Laos), Burma (Myanmar), on the Thailand/Burma border,
and Vietnam demonstrated that 38% and 53%, respectively,
of artesunate tablets contained no active ingredient.6,13 To
date, only artesunate labeled as made by Guilin Pharmaceu-
tical Co., Ltd. (Guilin, Guangxi, People’s Republic of China)
has been found to be counterfeit. Visual inspection, including
the examination of the holograms, bar codes, printing, crimp-
ing, color, size, weight, and consistency of the putative arte-
sunate tablets, was in good agreement with the colorimetric
test results in the first survey, but not in the second survey.
The counterfeiters appear to have responded to the increase
in public awareness by producing more sophisticated coun-
terfeit holograms and packaging, making it very difficult to
distinguish the counterfeit and genuine drugs.14,15
Little is known about the chemical composition of these
counterfeit medicines, the potential presence of toxic sub-
stances, or the fake artesunate production sources. Therefore,
we developed a liquid chromatography-mass spectrometry
(LC-MS) method to quantitatively evaluate the contents of
artesunate tablets, to validate the Fast Red TR colorimetric
test results, and to investigate the presence of other active
ingredients. Raman spectroscopy was used to characterize the
excipients present in the tablets and complement the LC-MS
analysis. We then used multivariate pattern recognition meth-
ods to examine the chemical similarities and differences be-
tween the chemical fingerprints of different types of fake tab-
lets, and to correlate these similarities with packaging char-
acteristics and sample origin.
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MATERIALS AND METHODS
Artesunate (CAS # 88495-63-0) and erythromycin, (CAS #
114-07-8) were obtained from Apin Chemicals Ltd. (Abing-
don, United Kingdom) and Fluka Biochemica (Buchs, Swit-
zerland), respectively. Artesunate standards were prepared in
high performance liquid chromatography (HPLC) grade
methanol (Sigma Aldrich, St. Louis, MO). Erythromycin
standards were prepared in a 50/50 solution (v/v) of HPLC
grade acetonitrile (Sigma Aldrich) and pure water (Barnstead
International, Dubuque, IA). Fresh standards were prepared
on a daily basis from stock solutions that were stored at 4°C.
Sample collection and preparation. A subset of 34 counter-
feit and genuine artesunate tablets from two surveys6,13 rep-
resenting the diversity of different packaging types recog-
nized in 2004 (see supplementary material in the report by
Newton and others15) were selected for LC-MS . Tablets were
crushed with a mortar and pestle and thoroughly homog-
enized; 100 mg of sample were suspended in 10 mL of a 50/50
acetonitrile/water (v/v) mixture and extracted on a rotary
shaker for two hours. All samples and standards were filtered
through a 0.45-m polytetrafluoroethylene membrane filter
(Pall Corporation, Ann Arbor, MI). Tablets and tablet ex-
tracts were kept refrigerated (4°C) until analysis. After pre-
liminary LC-MS runs, samples were diluted with methanol or
50/50 acetonitrile/water (v/v) as needed.
Characteristics of the packaging of fake artesunate tablets.
Fourteen different types of counterfeit artesunate tablet
samples, based on the packaging appearance and holograms,
have been described (see supporting information and Table
S1 in the report by Newton and others15). Type 1 counterfeit
artesunate bears no sticker or hologram, types 2, 5, 8, 11, and
12 bear foil stickers imitating the genuine hologram, and
types 3, 4, 6, 7, 9, 10, 13, and 14 bear hologram copies of the
genuine holograms.
Tablet testing by LC-MS. An introduction to LC-MS for
pharmaceutical analysis can be found elsewhere.17 All
samples were analyzed in a blind fashion to avoid any possible
bias in the analysis. The LC was performed on an Agilent
1100 system equipped with a solvent degasser, a binary pump,
a thermostated column compartment (held at 25°C), an au-
tosampler, and a diode array detector. A 2.1-mm internal
diameter, 150-mm long Zorbax Extend-C18 column (Agilent,
Palo Alto, CA) equipped with a precolumn was used. The LC
was operated at a flow rate of 200 L/minute, with an injec-
tion volume of 20 L. The binary pump used HPLC grade
water with 0.01% acetonitrile as mobile phase A and aceto-
nitrile as mobile phase B. For tablet fingerprinting, the LC
gradient started at 5% B and ramped to 45% B until 7 min-
utes, then increasing to 100% B from 7 to 8 minutes and held
at 100% B until 12 minutes. The system was set with a four-
minute post-run time to equilibrate the column to the original
mobile phase composition. To ensure maximum reproducibil-
ity in fingerprinting, all the organic extracts obtained from
fake tablets where run on the same day and by triplicate.
Blank runs were inserted between samples to eliminate car-
ryover. Artesunate was quantified as follows: HPLC grade
water with 0.01% methanol was used as mobile phase A and
methanol as mobile phase B. The LC solvent gradient started
at 35% B for 3 minutes, and then ramped to 100% B in 18
minutes, where it was held for 30 minutes. It was then ramped
back down to 35% B in 15 minutes. The retention time for
artesunate was 18.1 minutes.
The LC system was coupled to an AccuTOF time-of-flight
(TOF) mass spectrometer (JEOL, Peabody, MA) via an or-
thogonal electrospray interface operating at 2 kV. Although
negative ion mode electrospray ionization would seem the
first choice for artesunate analysis because of its carboxylic
acid functionality, positive ion mode also produces sufficient
sensitivity, and ensures detection of other compounds that
might be present in the sample. The ammonium [M + NH4]
+
(m/z  402) and sodium [M + Na]+ (m/z  407) artesunate
adduct ions were used for quantitation purposes. The MS
system allowed for accurate mass measurements with an av-
erage mass accuracy of 2 ppm at m/z  609. The NIST mass
spectral library (version 2.0 a) was used to search elemental
formulas of unknown compounds.18
Erythromycin was quantified by triplicate injections using
flow injection-MS as follows: a Vici Cheminert M6-liquid
handling pump (Valco Instruments Co. Inc. Houston, TX)
operated at 200 L/minute was connected to a manual six-
way HPLC injection valve equipped with a 20-L loop (Valco
Instruments Co. Inc.). The mobile phase consisted of 50%
acetonitrile in water. The area of the mass-selected chromato-
graphic peaks was integrated producing a linear calibration
curve between 2 nM and 145 nM.
Tablet testing by Raman spectroscopy. The analyses were
carried out on a Renishaw System-1000 spectrometer (Reni-
shaw, Wotton-under-Edge, United Kingdom) that was con-
nected to an Olympus (Center Valley, PA) BH-2 microscope.
The diode laser has a power of 50 mW at the source and a
wavelength of 785 nm (DL 100; TuiOptics GmbH, Martin-
sried/Munich, Germany). The collected Raman radiation was
dispersed with a 1,200 lines/mm grating and focused on a
Peltier-cooled CCD detector (Renishaw). All spectra were
recorded in the spectral window of 200 to 1800/cm, with 5
accumulations of 30 seconds. Vankeirsbilck and others pro-
vide an interesting review on the use of Raman spectroscopy
for pharmaceutical analyses.19
Data analysis. Time-resolved mass spectra were exported
from the AccuTOF instrument in ASCII format, resulting in
44 spectra, each one averaged over a 16.4-second retention
time interval. All LC-MS data was processed in Matlab ver-
sion 7.0 (The MathWorks, Natick, MA). After being exported
as ASCII files, each LC-MS run produced a 44 by 18,001 data
point matrix. The three matrices obtained for each triplicate
injection of identical sample extracts were averaged and pre-
pared for multivariate analysis by unfolding them into a single
44 × 18,001 792,044 element vector. This vector contained,
in one row, all mass spectra ordered by increasing retention
times. The vectors corresponding to the 23 fake artesunate
tablet samples were then combined into a single 23 by 792,044
matrix that was analyzed using K-nearest neighbor (KNN)
hierarchical clustering.20
RESULTS
Artesunate content. The mean (95% confidence interval)
artesunate content of artesunate tablets collected in Vietnam,
Burma, Thailand, Laos and Cambodia that tested positive in
the Fast Red TR colorimetric test was 55 (51–59) mg, except
for one tablet furnished with the genuine Guilin Pharmaceu-
tical Co., Ltd. hologram, which was collected in Siem Reap
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(Cambodia) and contained 21 mg of artesunate (Table 1).
This tablet was therefore considered substandard because it
does not meet the quality specifications set by this product by
the legitimate manufacturer.21 It was collected 13 months af-
ter date of manufacture as stated on the blisterpacket.
Artesunate tablets that tested negative by the Fast Red dye
test were all labeled as being manufactured by Guilin Phar-
maceutical Co. Ltd. (Guilin, Guangxi, People’s Republic of
China). Artesunate was not detectable in these tablets by
LC-MS (limit of detection < 1 g) (Table 2). Overall, 23
(68%) of 34 artesunate samples did not contain the expected
active ingredient and there was 100% agreement between the
Fast Red dye test results and the LC-MS results.
Identification of unexpected ingredients. During artesunate
quantitation, samples 12050, 12052, 12053, 12054, 12057,
12060, 12061, and 12062 (Table 2) had similar intense peaks in
the 700–750 m/z range that could not be assigned to any arte-
sunate dimer ions. Accurate mass analysis was performed on
sample 12053 and showed an exact mass value of 734.4703 Da
for the monoisotopic peak of the suspected ingredient, with
an elemental composition of C37H67NO13. A search within
the NIST mass spectral database18 returned a match corre-
sponding to the antibiotic erythromycin A with a theoretical
mass of 734.4691 Da. The total ion chromatograms of an
erythromycin standard and of sample 12053 showed matching
retention times of 13.38 and 13.55 minutes, respectively. The
fragmentation patterns for sample and standard were also
identical.22 The relative abundance of the [M + H]+ isotopic
peaks was also examined and was successfully matched to the
erythromycin standard, further confirming the identity of this
unexpected ingredient. Fake artesunate tablets contained a
total amount of erythromycin A that ranged from 20 to 191
mg/g of tablet (Table 2).
Erythromycin formulations generally contain more than
one type of erythromycin, with erythromycin A being the
most abundant.23 Inspection of the erythromycin spectral re-
gion showed several additional signals. Accurate mass mea-
surements were performed on all these peaks, and the follow-
ing erythromycins were identified: erythromycin B (theoret-
ical m/z  718.4714 Da, observed m/z  718.4742 Da);
erythromycin C (theoretical m/z  720.4534 Da, observed
m/z  720.4547); erythromycin E (theoretical m/z 
TABLE 1
Artesunate content for tablets that tested positive in colorimet-
ric tests*
Sample code Sample collection place
Artesunate content
(mg/tablet ± SD)
5† Mae La, Thailand/Burma border 54 ± 1
18‡ Ho Chi Minh City, Vietnam 51 ± 6
31§ Ho Chi Minh City, Vietnam 54 ± 5
32† Mueang Feuang, Laos 49 ± 6
39† Myitkyina, Burma 42 ± 12
12064¶ Sekong, Laos 62 ± 4
12065¶ Sekong, Laos 57 ± 3
12068¶ Attepeu, Laos 65 ± 14
13008† Siem Reap, Cambodia 21 ± 2
13013† Ko Kong, Cambodia 58 ± 3
63001# Phnom Phenh, Cambodia 56 ± 2
* The expected artesunate content is 50 mg/tablet.
† Guilin Pharmaceuticals, Guangxi, People’s Republic of China.
‡ Apharma, Hanoi, Vietnam.
§ Mekophar, Hanoi, Vietnam.
¶ Central Pharmaceutical Factory No. 1, Hanoi, Vietnam.
# European Community/World Health Organization Malaria Control Project, Cambodia.
TABLE 2
Sample origin and type of fake packaging sticker/holograms for tablets which tested negative in colorimetric tests*
Sample code† Sample collection place Fake hologram type
Erythromycin A content
(mg/g tablet ± SD) Paracetamol
Excipient detected by
Raman spectroscopy
Counterfeit artesunate with foil sticker imitations of genuine holograms
12054 Pakse, Laos 5 27 ± 4 No CaCO3
12061 Salavan, Laos 5 191 ± 7 Yes Not identified
12057 Pakse, Laos 8 58 ± 1 No CaCO3
12050 Pakse, Laos 8 50 ± 1 No CaCO3
12060 Salavan, Laos 8 < 1† Yes Not identified
12058 Pakse, Laos 8 Not detected No CaCO3
12052 Pakse, Laos 11 57 ± 5 Yes CaCO3
12062 Salavan, Laos 11 20 ± 5 Yes Not identified
12053 Pakse, Laos 5 < 1† Yes Not identified
13 Myitkyina, Burma 1 Not detected No Starch
980201 Ho Chi Minh City, Vietnam 1 Not detected No CaCO3
29 Ho Chi Minh City, Vietnam 2 Not detected No CaCO3
97 Ho Chi Minh City, Vietnam 2 Not detected No CaCO3
Counterfeit artesunate with hologram imitations of the genuine holograms
12051 Pakse, Laos 3 Not detected No Starch
13011/1 Anlong Veng, Cambodia 3 Not detected No Starch
13011/2 Anlong Veng, Cambodia 3 Not detected No Starch
12055 Pakse, Laos 3 Not detected No Starch
12071 Paksong, Laos 3 Not detected No Starch
12063 Salavan, Laos 3 Not detected No Starch
12067 Attepeu, Laos 3 Not detected No Starch
12056 Pakse, Laos 4 Not detected No Starch
12070 Paksong, Laos 4 Not detected No Starch
13007 Siem Reap, Cambodia Cutoff Not detected No CaCO3
* The classification of the fake stickers/holograms is detailed under supporting information. Artesunate was not detected in any of these samples. The printing on the blisterpack of specimen
13007 was unclear, suggesting that it was counterfeit. The presence of calcium carbonate suggests that it would have carried a foil sticker. All samples were labeled as if being manufactured by
Guilin Pharmaceutical Co. Ltd. (People’s Republic of China).
† Erythromycin A was detected, but the signal was too weak for accurate quantification.
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748.4483 Da, observed m/z  748.4503 Da); erythromycin F
(theoretical m/z  750.4640 Da, observed m/z  750.4633
Da), and anhydroerythromycin (theoretical m/z  716.4585
Da, observed m/z 716.4576 Da). Only erythromycin A was
detected in sample 12053 (Table S6).
Multivariate clustering of LC-MS chemical fingerprints. To
investigate the relationship between samples geographic ori-
gin, the content and type of erythromycins present and the
type of fake holograms observed on the packaging, multivari-
ate pattern recognition was performed on the LC-MS data.
Figure 1 shows the chemical fingerprint obtained by LC-MS
for a genuine Guilin Pharmaceutical Co., Ltd. artesunate tab-
let. Two intense peaks with a retention time of approximately
18 minutes are observed. The most intense signals (red) cor-
respond to the artesunate [M + NH4]
+ and [2M + NH4]
+
adduct ions (at 402 Da and 786 Da, respectively). Figure 2
FIGURE 1. Chemical fingerprint plot of a genuine artesunate tab-
let. M  artesunic acid. Larger red dots denote the most intense
signals and black small dots represent the weakest ones. Signals with
intermediate intensity were coded according to the color scale yellow
> green > cyan > blue. This figure appears in color at www.ajtmh.org.
FIGURE 2. Chemical fingerprint plots of fake artesunate tablets. Sample code is indicated within each plot. The x-axis represents m/z values
and the y-axis represents chromatographic retention time. This figure appears in color at www.ajtmh.org.
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shows contour plots of the LC-MS chemical fingerprints of 23
fake artesunate tablets. Comparison of Figures 1 and 2 clearly
demonstrates that none of the fake artesunate samples re-
sembles the genuine product in terms of chemical composi-
tion. However, several similarities among the fakes can be
readily found by visual inspection of their fingerprints.
Samples 12050, 12052, 12054, 12057, 12060, 12061, and 12062,
which were collected between December 2002 and January
2003, show similar fingerprints because of the presence of
erythromycins. Because of its lower erythromycin A content,
sample 12053 presented a different fingerprint than the afore-
mentioned samples. Raman spectroscopic analysis showed
that samples 12050, 12052, 12054 12057, and 12058 had a com-
mon excipient signature, which was confirmed to be CaCO3,
a common inorganic filler (Allen and others24). Genuine tab-
lets use maize starch, not CaCO3, as the excipient. Samples
12060, 12061, and 12062 contained erythromycin, but no
CaCO3 was detected. Calcium carbonate was also detected by
Raman spectroscopy in samples 980201, 29, and 97 from Viet-
nam and 13007 from Cambodia.
The chemical signatures of samples 13011/1 and 13011/2
from Along Veng, Cambodia are similar. These tablets come
from two different, but physically identical blister packs, that
were bought at the same time from the same shop. The lack
of refrigerated storage of the samples in shops and pharma-
cies in the seasonally high ambient temperatures in southeast
Asia (up to approximately 40°C) may be the cause of the
small differences between the samples’ fingerprints. These
two samples showed a similar polymeric peak eluting at 2
minutes, spaced by 162 Da, which corresponds to a hexose
unit. These signals originate from low molecular weight
starch-related excipients24, which were also detected by Ra-
man spectroscopy. Samples 12051, 12055, 12056, 12063, 12070,
and 12071 showed fingerprints similar to samples 13011-1 and
13011-2, also corresponding to a starch-related excipient.
Figure 3A shows the KNN dendrogram of the counterfeit
artesunate tablets’ LC-MS data. Samples 12054, 12061, 12057,
12052, 12050, 12062, and 12060 are clustered towards the top
portion of the dendrogram in a nested fashion. All these
samples were collected in different parts of southern Laos and
showed intense erythromycin signals. The ordering of these
samples in the dendogram followed their erythromycin A
content (Table 2), except for sample 12054 (containing 27 mg
of erythromycin A/g tablet), which was placed at the top of
the diagram. The fact that sample 12054 seems to be chemi-
cally unique is probably related to its different proportion of
anhydroerythomycin A, a hydrolysis product of erythromycin
A (Table S6), which indicates that a different (probably
older) batch of degraded erythromycin may have been used.
The sample grouping in the dendogram based on chemical
composition is also correlated with differences in the coun-
terfeit types as judged by the packaging. For example,
samples 12054 and 12061, which were placed in adjacent
branches of the dendogram, showed the same type of rainbow
foil sticker (type 5, not a true hologram but a sticker, see S1
in the report by Newton and others15) and were collected in
nearby Lao cities (Pakse and Salavan). These two samples
may come from separate batches that originated in a common
production source using unsophisticated fake stickers. How-
ever, accurate mass MS experiments in the low molecular
weight region showed that paracetamol (acetaminophen)
had been added to sample 12061, but not to sample 12054
(Table 2). Samples 12057, 12052, and 12050, which were also
obtained in Pakse, had type 8 or 11 fake foil stickers but are
chemically different from samples 12054 and 12061 in that
they all contain approximately 50 mg of erythromycin-A/g.
Samples 12052 and 12050 are further clustered, on the basis of
their chemical composition, because of their higher relative
percentage of erythromycin A in comparison to sample
12057.
Samples 12062 and 12060 were both collected in Salavan,
Laos and had rainbow foil stickers (types 11 and 8, respec-
tively) similar to samples 12057, 12052, and 12050. Their
erythromycin fingerprint is similar (between 80% and 90%
erythromycin A) but they differ in their absolute erythromy-
cin content. Raman and LC-MS also showed the presence of
paracetamol in both samples. Sample 12058 from Pakse (type
8), did not contain erythromycin, and seems to be placed
between the Laos samples containing erythromycins with
fake foil stickers and the remainder of the samples, which do
not contain erythromycins and are affixed with more elabo-
rate fake holograms.
The analysis of the similarities among samples without
erythromycins (Table 2) showed interesting trends (Figure
3B). Sample 13, which was collected in Myitkyina, Burma in
2000, had no fake holograms or stickers present on the pack-
aging (type 1). This sample is the most isolated from the rest
of the samples from a geographic point of view, but it showed
a Raman excipient signature consistent with starch similar to
two samples with type 3 fake holograms: samples 12051
(Pakse, southern Laos) and 12071 (Paksong, southern Laos),
collected in December 2002 and January 2003, respectively.
Sample 980201, which was collected in Ho Chi Minh City, also
had no fake sticker/hologram (type 1), but bore atypically
large printing font on the blisterpack and a simple chemical
fingerprint that partially resembled the fingerprint from Viet-
nam sample 29, which was affixed with a type 2 fake foil
sticker. These two samples contained CaCO3 and might have
been produced by the same manufacturing source, which
added a fake foil sticker to its product in response to in-
creased quality assurance measures put in practice by the
genuine manufacturer.
Samples with fake holograms type 3 and 4 are grouped
together at the bottom of the dendogram (Figure 3B).
Samples 12071 and 12063 seem to be almost identical chemi-
cally, with matching LC-MS fingerprints. Their packaging
showed a type 3 fake hologram and Raman analysis indicated
the presence of starch in both samples. Sample 12070, which
was collected in Paksong, was chemically similar to samples
12071 and 12063, but showed a more sophisticated type 4 fake
hologram. Samples 12051, 13011, 12056, and 12055 were col-
lected in Pakse, Laos and Anlong Veng, Cambodia (150 miles
away) and appear to be chemically related and similar to the
remainder of the samples detailed in Figure 3B. Sample 12056
showed a sophisticated type 4 fake hologram that was similar
to that found on sample 12070.
DISCUSSION
Between 1982 and 1999, 771 reports of counterfeit medi-
cines were received by WHO, 48.4% of which were from the
Western Pacific region, with most (51.2%) labeled as anti-
infectives.7 However, only 5–15% of the 191 WHO member
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states report cases of counterfeit drug7 and the “scale of the
problem . . . is shrouded in ignorance, confusion and de-
nial.”25 Antimalarials, among the most widely used drugs in
tropical countries, seem to have been particularly targeted by
counterfeiters. Of the 12 major antimalarial drugs used in the
world today, there are recent reports of counterfeits of 8.7
Counterfeit mefloquine and artesunate were first noticed in
Cambodia in 1998 when suspiciously inexpensive tablets were
found.26 A wide range of different counterfeit artesunate
types, based on packaging and fake holograms, have been
described and counterfeit artesunate has recently been found
in Yunnan, China.27 Artesunate tablets, such as sample 13008
from Cambodia, containing subtherapeutic amounts of arte-
sunate, whether they are counterfeit, substandard, or of re-
duced active ingredient because of poor storage, pose a great
danger to public health because they can create an environ-
FIGURE 3. A, K-nearest neighbor dendogram showing similarities between fake artesunate tablets. B, Detail of the samples not containing
erythromycins. Viet.  Vietnam; Camb.  Cambodia. This figure appears in color at www.ajtmh.org.
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ment that selects drug-resistant parasite strains.10,28 The in-
stability of some drugs kept in inadequate storage conditions
in tropical climates sometimes confounds drug quality assess-
ment and detection of substandard drug samples. For this
reason, it is not possible to assert if the insufficient levels of
artesunate observed in sample 13008 are a product of inad-
equate storage or inadequate manufacturing practices. As
shown in Table 1, samples collected prior to sample 13008,
such as samples 5, 18, 31, 32, and 39, contained the expected
amount of artesunate. Thus, we conclude that no noticeable
sample degradation was observed while stored in our facili-
ties. Alarmingly, small quantities of artesunate, which were
probably added to the preparations with the intention to de-
ceive the rapid colorimetric tests currently in use to detect
counterfeits,
15,29
have also been recently detected in counter-
feit antimalarial tablets packaged with fake holograms.
The second major anomaly observed, the presence of the
wrong active ingredients, is not uncommon in counterfeit
anti-infective drugs. Some of the early counterfeit artesunate
(collected in or before 1999) contained chloroquine that may
have been added to give the counterfeits a bitter taste because
there is a tradition in southeast Asia that antimalarials should
be bitter.26 However, chloroquine has very low antimalarial
efficacy throughout mainland southeast Asia and has been
abandoned as therapy for P. falciparum malaria.10 Recent
examples of unexpected ingredients in counterfeit anti-
infective drugs include a sulfonamide drug (sulfamethazine or
sulfisomidine) in counterfeit halofantrine syrup from west Af-
rica30 and chloramphenicol, metronidazole, pyrimethamine-
sulfadoxine, and metamizole in types of counterfeit artesu-
nate not examined in this study.29 These potentially danger-
ous pharmaceuticals, with no or minimal antimalarial action,
are probably leftover ingredients available to the counterfeit-
ers in a poor quality production process.
Examination of the relationship between chemical compo-
sition and packaging suggests two major clusters of artesunate
counterfeits, those with counterfeit foil stickers and contain-
ing CaCO3, erythromycin, and paracetamol, and those with
counterfeit holograms and containing starch but without
chemical evidence for the wrong active ingredients. In addi-
tion, of the two type 1 samples, one contained starch and one
contained CaCO3, suggesting that the so-called type 1 coun-
terfeit artesunate are a mixture of different recipes classified
together in error because of the lack of external packaging
clues.
That fake artesunate tablets prepared with different recipes
have been found in groups of neighboring cities either indi-
cates a common source of these fakes or a few sources (prob-
ably two or three) sharing a common distribution network.
Fake artesunate tablets of identical types are found in diverse
countries, with no clear spatial segregation into types, which
suggests a counterfeiting operation with a widespread distri-
bution network that extends across many porous borders.
This criminal counterfeiting operation has been flooding the
market with fake artesunate during the last eight years with
inevitable consequences in terms of increased malaria mor-
tality and morbidity.15
In summary, this study confirms the existence of fake arte-
sunate tablets with no detectable active ingredient, describes
the presence of one sample of sub-standard artesunate bear-
ing the manufacturer’s genuine hologram, and reports the
detection of different erythromycins and paracetamol in fake
artesunate. There was 100% agreement between the LC-MS
results and those obtained using the rapid, inexpensive col-
orimetric artesunate Fast TR dye test. The results also suggest
that a relationship between sample origin, chemical compo-
sition, and packaging exists.
Note: Supplemental Figures S1–S5 and supplemental Table
S6 appear online at www.ajtmh.org.
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